Figure 8
From: A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFκB activity
Real-Time PCR analysis of inflammation and angiogenesis in TAT-RH treated tumors. VEGF and TNFα expression was evaluated by Real Time PCR to assess the ability of TAT-RH to inhibit NFκB-dependent gene expression in cancer cells. At 2 weeks from starting treatment VEGF and TNFα expression is strongly inhibited in a dose dependent manner and prolonged treatments (4 weeks) increase such effect (*p < 0.05 vs control).